A Case Series of E-cigarette or Vaping-Associated Lung Injury With a Review of Pathological and Radiological Findings

Pourshahid, SeyedmohammadKhademolhosseini, SaraHussain, ShahzadIe, Susanti R.Cirino-Marcano, Maria Del MarAziz, SamehBiscardi, FrankForoozesh, Mahtab2023-06-282023-06-282022-05-082168-8184PMC9172897http://hdl.handle.net/10919/115561There has been a recent outbreak of e-cigarette or vaping-associated lung injury (EVALI) but the exact pathophysiology remains unknown. Tetrahydrocannabinol (THC) and vitamin E derivates are the major components in vaping-generated aerosols that are associated with EVALI. So far, there is no standard treatment for EVALI. Most cases are treated with antibiotics and steroids. Counseling for smoking cessation is an integral part of care for EVALI patients. Referral to addiction medicine may be beneficial. Considering the nonspecific presenting symptoms and the growing popularity of vaping devices, providers need to consider EVALI in the differential diagnosis of bilateral patchy ground-glass opacities with respiratory, constitutional, or gastrointestinal symptoms in patients using e-cigarettes. Here, we present four EVALI cases and review the pertinent imaging and pathological findings.application/pdfenCreative Commons Attribution 4.0 Internationale-cigarette and vaping product usee-cigarettese-smokingelectronic cigaretteslung pathologyoutbreakradiologic findingsvapingPreventionTobacco Smoke and HealthTobaccoLungSubstance MisuseClinical ResearchRespiratory3 Good Health and Well BeingA Case Series of E-cigarette or Vaping-Associated Lung Injury With a Review of Pathological and Radiological FindingsArticle - Refereed2023-06-28Cureushttps://doi.org/10.7759/cureus.24822145356933622168-8184